A Phase III Multicenter, Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Versus Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years

Trial Profile

A Phase III Multicenter, Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Versus Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cytarabine; Etoposide; Filgrastim; Fotemustine; Lenograstim; Melphalan; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms FIL-FLAZ-12
  • Most Recent Events

    • 29 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 25 Feb 2016 Planned End Date changed from 1 Jan 2018 to 1 Apr 2019 as reported by ClinicalTrials.gov.
    • 02 Nov 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2012-000251-14).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top